- 1. Epratuzumab
- [A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC). ( NCI )] (UMLS (NCI) C1120776) hLL2;
Humanized Anti-CD22 Monoclonal Antibody IgG1 =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
| - 4. Eprex
- (UMLS (NCI) C0376539) =Amino Acid, Peptide, or Protein; Pharmacologic Substance
|
- 2. Epratuzumab/Rituximab
- (UMLS (NCI) C1327878) =Therapeutic or Preventive Procedure ;
| - 5. Eprosartan
- [A competitive and reversible angiotensin II receptor antagonist with anti-hypertensive property. Eprosartan blocks the binding of angiotensin II to the angiotensin (AT)1 receptor in vascular smooth muscle, thereby blocking the principal pressor action of angiotensin II on the renin-angiotensin system resulting in vascular dilatation. In addition, this agent blocks angiotensin II -induced stimulation of aldosterone synthesis and secretion by the adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth. Furthermore, eprosartan inhibits sympathetic norepinephrine production, thereby further reducing blood pressure. ( NCI )] (UMLS (NCI) C0287041) =Organic Chemical; Pharmacologic Substance ;
=Acrylates;
imidazole;
[CV805] ANGIOTENSIN II INHIBITORS;
=(E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic Acid, Monomethanesulfonate;
|
- 3. Eprazinone
- (UMLS (NCI) C0059469) =Organic Chemical; Pharmacologic Substance ;
| - 6. Eprozinol
- (UMLS (NCI) C0059471) =Organic Chemical; Pharmacologic Substance ;
|
home
